Fedele Depalma, MD
Gastroenterology · Newark, DENPI 1952549610
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 37.4% of the total. 2025 is the largest year on record at $580, more than ten times the $42 reported in 2019. That places this record below the midpoint for gastroenterology clinicians in DE, where the typical reported total is $2,631.
Across 83 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$619
- Johnson & Johnson$199
- Ferring Pharmaceuticals Inc.$104
- Lilly USA, LLC$90
- Ardelyx, Inc.$88
- Takeda Pharmaceuticals U.S.A., Inc.$73
- plus $480 from 13 others
What the payments were for
- Food & beverage$1,653100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $619 |
| Johnson & Johnson | 8 | $199 |
| Ferring Pharmaceuticals Inc. | 6 | $104 |
| Lilly USA, LLC | 4 | $90 |
| Ardelyx, Inc. | 4 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $73 |
| Pfizer | 5 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $67 |
| Bristol Myers Squibb | 3 | $58 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| Boston Scientific | 3 | $37 |
| Micro-tech Endoscopy USA, Inc. | 2 | $34 |
| Celltrion USA Inc. | 1 | $30 |
| Olympus America Inc. | 2 | $29 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Novo Nordisk | 1 | $24 |
| Merck | 1 | $18 |
| QOL Medical, LLC | 1 | $14 |
How this compares
$1,653 in reported general payments places this provider in the 40th percentile of 50 gastroenterology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 14 | $35,667 |
| LinzessLinaclotide | 18 | $26,302 |
| Mesalamine | 23 | $12,595 |
| Omeprazole | 417 | $8,770 |
| Ursodiol | 23 | $4,971 |
| Esomeprazole Magnesium | 37 | $2,202 |
| Famotidine | 128 | $1,704 |
| Cholestyramine LightCholestyramine | 13 | $1,365 |
| Budesonide DrBudesonide | 13 | $1,143 |
| Lansoprazole | 13 | $874 |
| Pantoprazole Sodium | 42 | $710 |
| Sucralfate | 15 | $695 |
| Dicyclomine Hcl | 23 | $472 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $171 |
| Levofloxacin | 18 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $619 | $61,96932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 50 gastroenterology providers in Delaware.
Other gastroenterology in Newark
- Michael BrooksNewark$48K
- Jorge UribeNewark$11K
- Laura ConnorNewark$11K
- Gaurav JainNewark$10K
- Jared HossackNewark$9K
- Melissa VitoloNewark$8K
- Christine HerdmanNewark$7K
- Scott MeyersonNewark$7K
- Thirumaleshawar KanchanaNewark$7K
- Hasan AliNewark$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.